Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical
and Emotional Burden of Multiple Sclerosis
Cambridge,
MA – 25 May, 2016 – Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the launch of vs.MS, a global initiative focused on
highlighting and addressing the sometimes debilitating symptoms that accompany MS,
as well as their daily impact on people living with and affected by the
disease.
MA – 25 May, 2016 – Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the launch of vs.MS, a global initiative focused on
highlighting and addressing the sometimes debilitating symptoms that accompany MS,
as well as their daily impact on people living with and affected by the
disease.
This World MS Day, Sanofi Genzyme is putting a call out to the MS community
to learn more about the real impact of the disease and to declare themselves
vs.MS on the campaign website, www.vs-MS.com. For each vs.MS declaration, Sanofi Genzyme
will make a donation to the Multiple Sclerosis International Federation
(MSIF).
to learn more about the real impact of the disease and to declare themselves
vs.MS on the campaign website, www.vs-MS.com. For each vs.MS declaration, Sanofi Genzyme
will make a donation to the Multiple Sclerosis International Federation
(MSIF).
To inform the vs.MS campaign, a global survey was fielded among more
than 1,500 people living with relapsing MS (RMS) and their care partners in
seven countries: Australia, Canada, France, Italy, Spain, the United Kingdom
and the United States. Results from the
survey reveal the physical and emotional toll that RMS patients face on a
day-to-day basis. Additional survey
findings are available on the vs.MS website. Some findings include:
than 1,500 people living with relapsing MS (RMS) and their care partners in
seven countries: Australia, Canada, France, Italy, Spain, the United Kingdom
and the United States. Results from the
survey reveal the physical and emotional toll that RMS patients face on a
day-to-day basis. Additional survey
findings are available on the vs.MS website. Some findings include:
·
More than half of
respondents living with RMS find that issues with memory limit their daily
activities
More than half of
respondents living with RMS find that issues with memory limit their daily
activities
·
More than half of respondents
living with RMS say their ability to process information has slowed down
More than half of respondents
living with RMS say their ability to process information has slowed down
·
Nearly half of
respondents living with RMS feel limited by depression or anxiety
Nearly half of
respondents living with RMS feel limited by depression or anxiety
·
More than half of
respondents living RMS feel lonely or isolated because of their RMS
More than half of
respondents living RMS feel lonely or isolated because of their RMS
·
Two-thirds of respondents
living with RMS say their disease has affected their ability to keep their job
Two-thirds of respondents
living with RMS say their disease has affected their ability to keep their job
·
More than one-third of
respondents feel urinary problems associated with their RMS are a factor in the
decisions they make when planning to leave the house
More than one-third of
respondents feel urinary problems associated with their RMS are a factor in the
decisions they make when planning to leave the house
·
More than half of care
partner respondents do not discuss their fear of RMS progressing to avoid
upsetting the person they care for
More than half of care
partner respondents do not discuss their fear of RMS progressing to avoid
upsetting the person they care for
“As
part of our ongoing commitment to improving the lives of people affected by this
debilitating disease, we are proud to launch vs.MS,” said Carole Huntsman,
Global Multiple Sclerosis Lead, Sanofi Genzyme. “The
compelling findings from this survey broaden our understanding of the true
cognitive and emotional toll that MS takes, and will help guide our efforts to
better partner with the community to meet the overall needs of MS patients.”
part of our ongoing commitment to improving the lives of people affected by this
debilitating disease, we are proud to launch vs.MS,” said Carole Huntsman,
Global Multiple Sclerosis Lead, Sanofi Genzyme. “The
compelling findings from this survey broaden our understanding of the true
cognitive and emotional toll that MS takes, and will help guide our efforts to
better partner with the community to meet the overall needs of MS patients.”
To arm
the MS community with the tools and resources they need to be vs.MS, the campaign website includes videos, educational modules and survey results highlighting
the real burden of the disease.
the MS community with the tools and resources they need to be vs.MS, the campaign website includes videos, educational modules and survey results highlighting
the real burden of the disease.
To
learn more about vs.MS and view the survey findings, visit www.vs-MS.com and follow along on social media via the campaign hashtag, #vsMS.
learn more about vs.MS and view the survey findings, visit www.vs-MS.com and follow along on social media via the campaign hashtag, #vsMS.
About
Sanofi
Sanofi,
a global healthcare leader, discovers, develops and distributes therapeutic
solutions focused on patients’ needs. Sanofi is organized into five global
business units: Diabetes and Cardiovascular, General Medicines and Emerging
Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi
Sanofi,
a global healthcare leader, discovers, develops and distributes therapeutic
solutions focused on patients’ needs. Sanofi is organized into five global
business units: Diabetes and Cardiovascular, General Medicines and Emerging
Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Genzyme focuses on developing specialty treatments for
debilitating diseases that are often difficult to diagnose and treat, providing
hope to patients and their families. Learn more at www.sanofigenzyme.com.
debilitating diseases that are often difficult to diagnose and treat, providing
hope to patients and their families. Learn more at www.sanofigenzyme.com.
Genzyme® is a registered trademark of Genzyme
Corporation. Sanofi® is a
registered trademark of Sanofi. All
rights reserved.
Corporation. Sanofi® is a
registered trademark of Sanofi. All
rights reserved.
Sanofi Forward-Looking
Statements
Statements
This press release contains
forward-looking statements as defined in the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. These statements include projections and estimates
and their underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking information and
statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the FDA
or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that could affect
the availability or commercial potential of such product candidates, the
absence of guarantee that the product candidates if approved will be
commercially successful, the future approval and commercial success of
therapeutic alternatives, the Group’s ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in Sanofi’s annual report on Form 20-F for the year ended December
31, 2015. Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information or
statements.
forward-looking statements as defined in the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. These statements include projections and estimates
and their underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking information and
statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as the FDA
or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as
well as their decisions regarding labelling and other matters that could affect
the availability or commercial potential of such product candidates, the
absence of guarantee that the product candidates if approved will be
commercially successful, the future approval and commercial success of
therapeutic alternatives, the Group’s ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” in Sanofi’s annual report on Form 20-F for the year ended December
31, 2015. Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information or
statements.
Media Contact
Sanofi Genzyme Media Relations
Erin Walsh, +1 (617) 768-6881
==================================================================
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
Provides educational information, resources and services for those affected by MS
We Believe YOU (the MS Patients and Caregivers) should Be Empowered with Multiple Sclerosis information
Click here to receive MS news via e-mail
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews